Please ensure Javascript is enabled for purposes of website accessibility

Could This Drug Be 100% Effective in Preventing Symptomatic COVID-19 Infections?

By Jim Crumly – Jan 28, 2021 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Strong interim trial data boosts the prospects for a treatment already worth billions.

While the world focuses on the rollout of COVID-19 vaccines, antibody treatments that can be given to patients after they've contracted the disease haven't been in the spotlight. New data from Regeneron Pharmaceuticals (REGN 1.32%) suggests that investors might do well to sit up and listen.

Regeneron's cocktail of two monoclonal antibodies synthesized to block the SARS-CoV-2 virus got plenty of press when it was given to President Trump, who subsequently recovered from COVID-19. In November 2020, Regeneron won emergency use authorization from the Food and Drug Administration for the cocktail, called REGN-COV2, in treating patients with mild to moderate cases of the disease. It also scored a contract with the U.S. government to supply 300,000 doses. That deal was just the beginning.

SARS-CoV-2 virus under attack by antibodies.

Image source: Getty Images.

100% effectiveness in preventing symptomatic disease, so far

Regeneron is conducting a trial to evaluate the usefulness of REGN-COV2 in preventing infection in the first place. This type of prevention is called "passive immunization," a process that confers short-term immunity immediately, instead of taking weeks like vaccines. The company released interim results from the trial this week. The data so far is stunning.

So far, 409 patients have been evaluated. Subjects are randomized to get either REGN-COV2 or a placebo. The participants were selected from people at high risk of infection due to being exposed to a household member diagnosed with COVID-19. The antibody cocktail was administered as a simple injection, rather than via IV infusion as required in the current authorization.

None of the patients receiving the cocktail developed a symptomatic case of COVID-19, compared with eight in patients given the placebo. The incidence of asymptomatic cases was about half of that in the placebo group. What's more, the asymptomatic cases in the REGN-COV2 cohort had infections that lasted no more than a week, while 40% of the infections in the placebo group lasted three to four weeks. Analysis showed that the treated patients who became infected had significantly reduced viral loads compared to the placebo group. They were also apparently less contagious.

The trial is far from over, having enrolled over 2,000 participants. That perfect record against symptomatic disease probably won't hold. Still, a successful trial could result in authorization for using the treatment to prevent the disease in people known to be exposed to the virus, potentially opening huge demand.

More good news

Regeneron is also testing the use of REGN-COV2 in hospitalized patients who aren't sick enough to need a ventilator. Data released in December was encouraging, with the treatment lowering the risk of ventilation or death by 22%. The treatment also seems to be effective against both the U.K. and South African variants.

But the best news for investors in recent weeks is that the U.S. government has significantly upped its purchases of the antibody cocktail. Operation Warp Speed has agreed to buy as many doses as Regeneron can make before June 30, 2021, up 1.25 billion more than the original agreement. If the company succeeds in getting authorization for a lower dose than was specified in the original authorization, it expects it will be able to manufacture all the 1.25 billion new doses. If it hits that target, the new deal is worth $2.65 billion, thanks to a price tag of over $2,000 per dose. That's a huge boost to the company's results, with analysts expecting 2020 revenue to come in at only $8.5 billion.

Plenty of long-term value

Investors don't seem to be giving Regeneron much credit for its COVID-19 efforts despite the obvious success. Shares are selling for roughly the same multiple of forward earnings as they did when the pandemic began.

2-year graph of Regeneron forward PE.

Data source: YCharts.

Meanwhile, Regeneron has a healthy pipeline of new drugs in its core cancer, inflammatory disease, and eye disease businesses. The company has six phase 3 programs, 13 of which are in phase 2. It could make six regulatory submissions in 2021. Its four core drugs generated 29% revenue growth in the first nine months of 2020.

I think investors are overly focused on vaccine stocks and not recognizing the pile of money Regeneron will almost certainly make from its antibody cocktail, especially in light of recent news. Even without the pandemic, the company would be a promising pick for biotech investors looking for long-term growth.

Jim Crumly owns shares of Regeneron Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$697.33 (1.32%) $9.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.